Targeted Therapy in Hepatocellular Carcinoma by Chua, Clarinda W. L. & Choo, Su Pin
SAGE-Hindawi Access to Research
International Journal of Hepatology
Volume 2011, Article ID 348297, 11 pages
doi:10.4061/2011/348297
Review Article
Targeted Therapy in HepatocellularCarcinoma
ClarindaW. L.ChuaandSuPinChoo
Department of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610
Correspondence should be addressed to Clarinda W. L. Chua, chua.wei.ling@nccs.com.sg
Received 18 January 2011; Accepted 1 March 2011
Academic Editor: Thomas Leung
Copyright © 2011 C. W. L. Chua and S. P. Choo. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide, as well as a common cause of cancer-related death.
HCC frequently occurs in the setting of a diseased cirrhotic liver and many patients present at an advanced stage of disease.
Together with a poor functional status, this often precludes the use of systemic therapy, especially conventional cytotoxic drugs.
Moreover, HCC is known to be a relatively chemo-refractory tumor. There have been many targeted drugs that have shown
potential in the treatment of HCC. Many clinical trials have been carried out with many more in progress. They include trials
evaluating a single targeted therapy alone, two or more targeted therapy in tandem or a combination of targeted therapy and
conventional chemotherapy. In this article, we seek to review some of the more important trials examining the use of targeted
therapy in HCC and to look into what the future holds in terms of targeted treatment of HCC.
1.Introduction
Liver cancer is the sixth most common cancer worldwide,
accounting for 5.7% of new cancer cases, and the third most
common cause of cancer-related death [1]. The majority of
cases and deaths occur in developing countries. Of the
primary liver tumors in adults, hepatocellular carcinoma
(HCC) is the commonest [2].
HCC frequently occurs in the setting of a diseased cirr-
hotic liver. It has well-deﬁned risk factors, the most common
beinginfectionswithhepatitis Bvirus(HBV)andhepatitis C
virus (HCV). Chronic excessive alcohol consumption, envi-
ronmental toxins, for example, aﬂatoxin B and nonalcoholic
steatohepatitis (NASH), make up the rest of the main causes.
The etiological factors vary by geographical locations [3]. In
AfricaandEastAsiancountriesincludingTaiwan,China,and
Korea, HBV is the main cause whereas in the West and in
Japan,HCVisthemainriskfactor,togetherwithothercauses
of cirrhosis including alcohol [3, 4].
The asymptomatic nature of a HBV and HCV carrier
state, the insidious presentation of early HCC, and screening
programs that are not properly deﬁned or adhered to results
in the majority of patients with HCC presenting at an
intermediateoradvancedstate.Potentiallycurativestrategies
such as resection and transplantation as well as loco-regional
therapies such as radiofrequency ablation and transarterial
chemoembolization are often not possible at these stages.
Systemic treatment with chemotherapy is not routinely
employed in the treatment of advanced HCC for a variety
of reasons. As HCC usually occurs in the context of a
diseased cirrhotic liver, poor hepatic reserves often preclude
or limit systemic chemotherapy. Also, HCC is known to
be a relatively chemorefractory tumor, in part due to
overexpression of drug-resistant genes including MDR1 [5].
Trials involving chemotherapeutic agents were carried out
in diverse populations, limiting their application across the
board to the entire cohort of HCC patients.
Several studies of chemotherapeutic agents have shown
them to have limited activity in HCC [6–8]. Various clinical
trials investigating the role of single-agent chemotherapy on
the other hand have previously reported response rates from
0% to 20%. Anthracyclines, for example, doxorubicin have
shown a response rate of up to 20% [9–12]; their usage,
though, has been limited by elevated toxicity.
A randomized phase III study by Yeo et al. [13]r e p o r t e d
a response rate of 21% using PIAF (cisplatin, doxorubicin,
interferon, and ﬂuorouracil) in 91 of 94 assessable patients
with unresectable HCC with a median overall survival (OS)
of 8.7 months. Lombardi and colleagues demonstrated a
response rate of 24% with pegylated liposomal doxorubicin2 International Journal of Hepatology
and gemcitabine in patients with advanced HCC [14]. In this
study, one patient went on to undergo liver transplantation
and another underwent surgical resection. About half of the
patients were Child-Pugh B.
Although chemotherapy in advanced HCC has been
shown in various trials to have relatively signiﬁcant response
rates, its usage is limited by toxicities, especially in patients
with poor hepatic reserves. Moreover, the phase III trial
using PIAF did not show survival beneﬁt over single agent
doxorubicin alone.
The poor prognosis of patients with advanced or meta-
static HCC, with a median survival of a few months [15],
coupledwithsuboptimalchemotherapyeﬃcacyandinability
ofpatientswithpoorliverfunctiontotoleratechemotherapy,
has resulted in a need for alternative treatment strategies.
2. Molecular Pathogenesis of HCC
Two main mechanisms are thought to predominate in the
pathogenesis of HCC. The ﬁrst being cirrhosis after tissue
damage resultant from either HBV, HCV infections or toxins
such as aﬂatoxin B and from metabolic causes including
obesity and NASH [16, 17]. The second is that of oncogene
o rt u m o rs u p p r e s s o rg e n em u t a t i o n s[ 18–23]. Both are asso-
ciated with abnormalities in cell signaling pathways. Target-
ing various levels in the signaling cascade may help in both
the chemoprevention and the treatment of HCC.
Various signaling pathways have been implicated in
HCC, including VEGFR, EGFR, ERK/MAPK, and mTOR,
among others [17, 24].
3.VascularEndothelialGrowthFactor
Receptor (VEGFR)Pathway
HCC is a vascular tumor and is dependent on angiogenesis
for growth. Important growth factors include vascular endo-
thelial growth factor (VEGF), platelet-derived growth factor
(PDGF), epidermal growth factor (EGF), angiopoietins, and
ﬁbroblast growth factors. These induce angiogenic signal-
ing via various pathways, including the activation of the
RAF/ERK (extracellular regulated kinase)/MAPK (mitogen-
activated protein kinase), mammalian target of rapamycin
(mTOR), and WNT-signaling transduction pathways.
Adult hepatocytes are able to upregulate the production
of the growth factors listed above following liver damage
or injury. This up-regulation is usually transient but poses
a problem when it becomes dysregulated in a chronically
injured liver, leading to sustained growth signaling [25].
Vascular endothelial growth factor (VEGF) is a primary
mediator of angiogenesis in HCC [26, 27]. The upregulation
of VEGF and increased expression of VEGFR have been
demonstrated in both HCC cell lines and serum of HCC
patients [28–32].
The disruption of the VEGFR pathway and targeting
growth factors that drive the angiogenic process can thus
interrupt eﬀective angiogenesis and have clinical eﬀect in the
treatment of HCC. Antiangiogenic drugs such as sorafenib
and bevacizumab target diﬀerent points along the VEGFR
pathway.
4. Sorafenib
Sorafenib(Nexavar,BayerHealthCarePharmaceuticals-Onyx
Pharmaceuticals) is an oral multikinase inhibitor. It has po-
tent eﬀects against VEGFR-2, VEGFR-3, and PDGFR and
also targets kinases of wild-type B-Raf, mutant V559EB-Raf,
and C-Raf [25]. Its main action is thought to be that of com-
petitively inhibiting ATP binding to the catalytic domains of
the various kinases [33].
Preclinical experiments in mouse xenograft model of hu-
man hepatocellular carcinoma showed that sorafenib had
antiproliferativeactivityandthatitreducedtumorangiogen-
esis and tumor cell signaling as well as increased tumor cell
apoptosis [34].
AphaseIIstudybyAbou-Alfaetal.[35](seealsoTable 1)
of 137 patients with advanced HCC showed that high pre-
treatmentlevelsofpERK(phosphorylatedextracellularregu-
lated kinase) correlated with a longer time to progression
(TTP) following treatment with sorafenib. This suggests that
tumors containing higher levels of pERK are more sensitive/
responsive to sorafenib and that the Raf/ERK/MEK pathway
has an important role in HCC. Signiﬁcantly, it has also iden-
tiﬁed pERK as a potential biomarker with predictive signiﬁ-
cance in HCC.
Inthisstudy,34%ofpatientsachievedstabledisease(SD)
for at least 16 weeks and 8% achieved partial response (PR)
or minor response (MR). The median OS was 9.2 months.
Comparedtohistoricalcontrols,theresultsappearfavorable.
For example, single-arm studies evaluating combination
therapy (cisplatin, interferon, doxorubicin and ﬂuorouracil
(PIAF) or doxorubicin plus cisplatin) in HCC patients [36,
37] demonstrated median overall survival (OS) of 8.9 and
7.3 months and SD rates of 28% and 16%, respectively.
Important grade 3/4 adverse events observed included
hand-foot skin (HFS) reaction, diarrhea, and fatigue, but
they were infrequently dose-limiting. No clinically relevant
pharmacokinetic diﬀerences between Child-Pugh (CP) Class
A and Class B patients were noted, and it is unlikely that any
dose adjustment is required when administering sorafenib to
these 2 groups of patients.
Ofnote,72%ofpatientswereclassiﬁedasCPClassAand
28% as CP Class B. 17% were HBV positive and 48% were
HCV positive.
Two subsequent pivotal studies then led to the approval
of sorafenib for the treatment of advanced HCC in the USA
and Europe [38, 39].
The Sorafenib Hepatocellular Carcinoma Assessment
Randomized Protocol (SHARP) [38] trial by Llovet et al.
was concluded early after the second interim analysis showed
that advanced HCC patients treated with sorafenib had a
signiﬁcant survival beneﬁt over placebo-treated controls.
This was a multicenter, double-blinded, and placebo-
controlled phase 3 trial of 602 patients with advanced HCC
with no previous systemic therapy randomized to either
400mg of sorafenib twice daily or matching placebo. Treat-
ment was continued until the occurrence of both radiologic
progression as deﬁned by RECIST [40] and symptomatic
progression as deﬁned by the Functional Assessment of
Cancer Therapy-Hepatobiliary Symptom Index 8 (FHSI8)International Journal of Hepatology 3
Table 1
Agent Study Phase Comparator
arm
No. of
patients Response rate
TTP
(median
months)
OS
(median
months)
AEs
Sorafenib Abou-Alfa et
al. [35] II — 137 34% SD
8% PR/MR —9 . 2 HFS, diarrhea,
fatigue
SHARP trial
Llovet et al.
[38]
III Vs placebo 602 2% PR
No CR 5.5 versus 2.8 10.7 versus
7.9
HFS (21%),
diarrhea
(39%)
Cheng et al.
[39] III Vs placebo 271 — 2.8 versus 1.4 6.5 versus 4.2
HFS (45%),
diarrhea
(26%), rash
(20%), fatigue
(20%)
Sorafenib +
TACE
START trial
Chung et al.
[41]
II — 50
(evaluable)
36% CR
60% PR/SD —— —
Sorafenib +
doxorubicin
Abou-Alfa et
al. [42] II Vs
doxorubicin 96 — 6.4 versus 2.8 13.7 versus
6.5
Same both
arms
Bevacizumab Siegel et al.
[43] II — 46 13% PR
53% (1yr)
28% (2yr)
23% (3yr)
Hypertens ion
(15%),
thrombos is
(6%)
Bevacizumab +
gemcitabine +
oxaliplatin
Zhu et al.
[44] II — 30
(evaluable)
20% RR
27% SD —9 . 6 —
Bevacizumab +
capecitabine +
oxaliplatin
Sun et al. [45]I I — 30
(evaluable)
13% PR
77% SD 4.5 10.3 —
Bevacizumab +
capecitabine
Hsu et al.
[46] II — 45
9% RR
52%
CR/PR/SD
2.7 (PFS) 5.9 HFS 9%
BGIT 9%
Bevacizumab +
erlotinib
Thomas et al.
[47] II — 40 — 9 (PFS) 15.6
BGIT 13%,
fatigue 20%,
hypertens ion
15%
Sunitinib Zhu et al.
[48] II — 34 50% SD 4.1 — —
Faivre et al.
[49] II — 37 2% PR
35% SD 3.7 (PFS) 8
Signiﬁcant 4
deaths,
trial stopped
ABT-69 Toh et al. [50]I I — 44 (34
evaluable)
8.7% (23 CP
Ap t s ) 3.7 9.8 Mostly mild
mod
Erlotinib Philip et al.
[51] II — 38 9% PR 32% (6
months PFS) 13 —
Thomas et al.
[52] II — 40 — 28% (6
months PFS) 3.3 —
RR: overall response rate, MR: minor response, PR: partial response, SD: stable disease, CR: complete response, PFS: progression-free survival, TTP: time to
progression, OS: overall survival, AEs: adverse events, HFS: hand-foot syndrome, BGIT: bleeding gastrointestinal tract, CP A: Child Pugh A.
questionnaire or the occurrence of either unacceptable adve-
rse events or deaths.
The results were encouraging, with a median OS of 10.7
months in the sorafenib group versus 7.9 months in the
placebo-treated group (hazard ratio in the sorafenib group,
0.69; 95% conﬁdence interval (CI), 0.55 to 0.87; P<. 001).
Although there was no signiﬁcant diﬀerence between the
two groups in the median time to symptomatic progression
(4.1 months versus 4.9 months, respectively, P = .77), the
median time to radiologic progression was almost doubled,
5.5 months in the sorafenib group versus 2.8 months in the
placebo group (P<. 001). 7 patients (2%) in the sorafenib
group and 2 (1%) in the placebo group had a PR, no patient
had a complete response (CR).4 International Journal of Hepatology
Similar to the phase II trial by Abou-Alfa et al. [35],
HFS, diarrhea, and weight loss were the most common side
eﬀects in the sorafenib group. Adverse eﬀects reported for
patients receiving sorafenib were predominantly grade 1 or 2
inseverityandmainlygastrointestinal,dermatologic,orcon-
stitutional in nature. In particular, diarrhea, hand-foot skin
reactions(HFS),weightloss,alopecia, andanorexia weresig-
niﬁcantlymorecommonin thesorafenibgroupcomparedto
the group receiving placebo. Grade 3 adverse eﬀects included
diarrhea (8% in sorafenib group versus 2% in placebo group,
P<. 001) and HFS (8% versus <1%, P<. 001). Except
for grade 3 hypophosphatemia (11% versus 2%, P<. 001),
grade 3 or 4 laboratory abnormalities occurred at similar fre-
quencies in both groups. The most common adverse events
leading to sorafenib discontinuation were gastrointestinal
events (6%), fatigue (5%), and liver dysfunction (5%). The
rate of discontinuation of study drug due to adverse events,
however, was similar in both groups (38% versus 37%).
This was the ﬁrst phase III study of a systemic therapy to
have shown a survival advantage in patients with advanced
HCC. In this group of patients with advanced HCC, the
median OS and time to radiologic progression were nearly 3
months longer for patients treated with sorafenib than those
given placebo.
Thisgroupofpatientswascarefullyselected,withthema-
jority having eastern cooperative oncology group (ECOG)
performance status of 0 or 1 and the remainder ECOG 2
status. They were CP Class A. 56% of the patients had HCV.
A second similar study was conducted in Asia with 271
patients with advanced (unresectable or metastatic) HCC
[39]. None had prior systemic therapy, and all had CP Class
A. This trial had no predeﬁned primary endpoint, and the
objective was to assess the eﬃcacy and safety of sorafenib in
Asia-Paciﬁc patients with advanced HCC.
Median OS was 6.5 months (95% CI 5.56–7.56) in pati-
ents treated with sorafenib compared to 4.2 months (95%
CI 3.75–5.46) in the placebo group, hazard ratio 0.68 (95%
CI 0.50–0.93, P = .014). Median time to progression (TTP)
was 2.8 months in the sorafenib group and 1.4 months in
the placebo group. There was no signiﬁcant diﬀerence in the
time to symptomatic progression (TTSP) between the two
groups.
Like in the previous studies, sorafenib was generally well
tolerated with manageable side eﬀects. The most common
drug-related adverse events in the sorafenib group were HFS
(67 out of 149 patients (45%)), diarrhea (38 of 149 (25.5%)),
alopecia (37 of 149 (24.8%)), fatigue (30 of 149 (20.1%)),
rash or desquamation (30 of 149 (20.1%)), hypertension (28
of 149 (18.8%)), and anorexia (19 of 149 (12.8%)). These
were predominantly grade 1 or 2 adverse events.
In comparison, overall incidence of HFS was 21% and
diarrhea 39% in the SHARP study. In this Asian study,
treatment discontinuation due to adverse events was similar
in both groups (19.5% versus 13.3%). Dose reductions due
to adverse events were required in 30.9% (46 of 149 patients)
of patients in the sorafenib group compared to 2.7% (2 of
75) in the placebo group. Most common reasons for dose
reductions in the sorafenib group were HFS (11.4%) and
diarrhea (7.4%).
Although the absolute survival was greater in the SHARP
trial for both study groups, the hazard ratios (HRs) for
survival (i.e., reduction in the risk of death associated
with sorafenib treatment) was comparable between the two
studies (0.68 in the study by Cheng et al. [39] and 0.69 in
the SHARP trial [38]). This suggests that there is comparable
eﬃcacy for sorafenib in both studies and that there are
diﬀerences in the patient population in the two studies.
Indeed, at baseline, more patients had extrahepatic spre-
ad, greater number of hepatic tumor lesions, poorer ECOG
status and higher alpha-fetoprotein (AFP) levels in the study
by Cheng et al. than in the SHARP trial. It may well be than
the patients enrolled in the former study had more advanced
disease than those in the latter, accounting for the diﬀerence
in the absolute survival for both sorafenib and placebo gro-
ups across the two studies.
However, other signiﬁcant diﬀerences exist between the
two studies. As previously stated, etiological factors for
HCC in the Asia-Paciﬁc region diﬀer from other regions.
For example, 73% of the patients in the study by Cheng
et al. had baseline HBV infection and 8.4% had baseline
HCV infection, compared with 12% and 30% for HBV and
HCV, respectively, in the SHARP trial. There has been some
evidence that patients with HBV-associated HCC may have
worse prognosis that those with HCV-related HCC [53]a n d
others which suggests sorafenib may be less eﬃcacious in
HBV patients [54].
A subset analysis of their patients with HBV infection
showed that those treated with sorafenib had longer OS and
TTP than those given placebo, and another study showed
that the safety proﬁle of sorafenib in HBV patients was
similar to the overall study population [55], leading the
authors to conclude that sorafenib is just as eﬃcacious in
HBV patients.
Subgroup analysis of patients with HCV in the SHARP
study showed similar safety proﬁle in the 178 patients with
HCV compared to the overall population [56]. Adverse
events weremostly predictable andmanageable.OS and TTP
in this subset of patients were similar to those of the overall
study population. These ﬁndings support the eﬃcacy and
safety results reported in the SHARP trial in patients with
HCC and demonstrate a consistent clinical beneﬁt regardless
of HCV status.
Although sorafenib is approved in the USA for the
treatment of all unresectable advanced HCC based on the
trials above, the results need to be interpreted with caution.
In both trials, patients recruited were CP Class A and had
relatively good performance status (ECOG 2 or less). These
patients were chosen as it was felt liver function impairment
associatedwithCPClassBorCmaypotentiallyconfoundthe
results of the study. Hence, the eﬀect of sorafenib in patients
with poor liver function or decompensated liver disease is
still unclear.
The study by Abou-Alfa et al. [35] suggests no diﬀerence
in the tolerability of sorafenib in patients with CP Class A
or B disease. Updated data from this trial suggests a similar
pharmacokinetic and toxicity proﬁle for CP Class A and B
patients [57]. 28 out of 137 patients had blood samples ana-
lyzed for pharmacokinetics (21 CP A and 7 CP B patients).International Journal of Hepatology 5
AUC (0–8) and Cmax were comparable, as were incidence
rates for all adverse events and serious adverse events.
Elevated bilirubin in this analysis may be related to sorafenib
inhibition of UGT1A1 activity. As expected, CP B patients
did worse than CP A patients, with more frequent worsening
oftheirlivercirrhosis. Itwasunclear,though,ifthiswasdrug
related or due to underlying disease progression. More data
is needed to conﬁrm the safety and eﬃcacy of sorafenib in
CP B patients.
Pinter et al. [58] also reported a retrospective series eva-
luating sorafenib in 59 patients, 40% of whom had CP Class
B disease and 17% CP Class C disease. The median survi-
val times for these patients with CP Class A, B, and C dise-
ase were 8.3, 4.3, and 1.5 months, respectively, leading the
authors to conclude that there was no beneﬁt from systemic
targeted therapy in patients with very advanced HCC. A
phase I and pharmacokinetic study suggested that sorafenib
doses should be titrated against the bilirubin levels (an indi-
cationofdegreeofliverdysfunction)andpatientswithsevere
liver impairment may not even be able to tolerate attenuated
doses [59].
Further studies to evaluate and conﬁrm the beneﬁts and
safety of sorafenib in HCC patients with poorer liver func-
tion are required. Also the role of sorafenib as an adjuvant
therapy after resection or locoregional therapy needs to be
studied, as well as the eﬃcacy of combining sorafenib with
either chemotherapy or other targeted therapies.
START, a phase II study of the combination of tran-
scatheter arterial chemoembolization (TACE) with sorafenib
in Asian patients with unresectable HCC is still ongoing
[41]. The second interim analysis of 50 patients evaluable for
eﬃcacy showed that 20 (40%) did not require more than 2
TACEprocedures.Andofthese,18achievedaCRwhile2had
progressive disease. The remainder 30 had PR or SD. Grade
3 adverse events (AEs) occurred in 38 patients (60%), most
common of which was hand-foot syndrome. There was 1
grade4AE(ASTelevation).AllAEsimprovedwithsorafenib
dose modiﬁcation, and no patient discontinued due to AE.
Preliminary data hence shows that the combination of TACE
and sorafenib is safe and tolerable, and further results are
awaited.
A phase II trial evaluating the safety and eﬃcacy of doxo-
rubicin plus sorafenib compared to doxorubicin alone in
patients with advanced HCC, and CPA disease was conduc-
ted by Abou-Alfa and colleagues [42]. In this study, patients
were randomly assigned to receive 60mg/m2 of doxorubicin
intravenously every 21 days plus 400mg of either sorafenib
or placebo orally twice a day. Ninety-six patients were acc-
rued and following complete accrual, an unplanned early
analysis for eﬃcacy was performed and the trial was halted.
The median time to progression was 6.4 months in the
doxorubicin-sorafenib group and 2.8 months in the doxo-
rubicin-placebo group. PFS was 6.0 months, and 2.7 months
and median OS was 13.7 months and 6.5 months in these
2 groups, respectively. Toxicity proﬁles were similar to those
for single agents.
Synergism between sorafenib and doxorubicin is postu-
lated to be the reason behind the improved TTP, OS, and
PFS in the group on combined therapy. An ongoing phase
III study in advanced HCC patients comparing sorafenib
with and without doxorubicin is underway [60]. This
combination is as yet not indicated for routine clinical use.
YauandChanconductedaphaseIItrialofsorafenibwith
capecitabine and oxaliplatin (SECOX) in 51 patients with
locally advanced or metastatic hepatocellular carcinoma
[61]. In this single-arm, multicentre study, the SECOX
regime demonstrates signiﬁcant clinical activity and good
tolerability in this group of patients.
Eighty-four percent of patients were chronic HBV carri-
ers,and98%hadCPAcirrhosis.Thebestresponserate(RR)
was 14%, and 61% achieved SD, with median TTP being
7.1 months and OS 10.2 months. Toxicities were mainly
grade 1 or 2, with hand-foot syndrome (73%), diarrhea
(69%), and neutropenia (63%) being the most commonly
encountered.
Notwithstanding the above studies, sorafenib as single
agent remains the only drug so far that has shown overall
survival beneﬁt over placebo in a multicentre, double-blind,
placebo-controlled randomized phase III trial in patients
with advanced HCC [38, 39].
5.Bevacizumab
Bevacizumab (Avastin; Genentech, Inc, South San Francisco,
CA,USA)isarecombinanthumanizedmonoclonalantibody
directed against VEGF [62]. Bevacizumab is also used in the
treatment of other malignancies including colon, breast, and
kidney cancer. It has been studied both as a single agent, as
well as in combination with chemotherapeutic or targeted
agents, for example, erlotinib, in the treatment of patients
with advanced HCC.
A phase II study of 46 patients using bevacizumab alone
in unresectable HCC by Siegel et al. [43]r e p o r t e da1 3 %
partial response (PR). The 6-month progression-free sur-
vival(PFS)was65%.Overallsurvival(OS)at1,2,and3years
was 53%, 28%, and 23%, respectively. Grade 3 to 4 adverse
events included hypertension (15%) and thrombosis (6%,
including 4% with arterial thrombosis). Grade 3 or higher
hemorrhage occurred in 11% of patients, including one fatal
variceal bleed.
Bevacizumab was also evaluatedin various combinations
with chemotherapy including gemcitabine and oxaliplatin
[44],capecitabineandoxaliplatin[45]andcapecitabine[46].
Zhu et al. showed that combining bevacizumab with
gemcitabine and oxaliplatin resulted in a 20% overall res-
ponse rate in evaluable patients and stable disease in 27%.
The median OS was 9.6 months, and median PFS was 5.3
months [44].
A phase II trial performed to evaluate the combination
of bevacizumab with capecitabine and oxaliplatin reported a
median OS of 10.3 months and a median time to progression
(TTP) of 4.5 months. 13.3% (4 out of 30 evaluable patients)
had PR and 76.6% (23 patients) had SD [45].
Bevacizumab in combination with capecitabine was
evaluated in a study by Hsu et al. [46]. Overall response rate
was 9% and 52% of patients achieved CR, PR, or SD.
A trial of anti-EGFR therapy (Erlotinib) with bevaci-
zumab is reported below.6 International Journal of Hepatology
6.Sunitinib
Sunitinib (Sutent; Pﬁzer Labs, New York, NY, USA) is ano-
ther oral tyrosine kinase inhibitor that blocks several recep-
tors, including VEGFR1, 2 and 3, PDGFR-β, c-kit, and FLT3
and RET kinase. Most antiangiogenic eﬀects of sunitinib are
shown in preclinical studies to be mediated via VEGFR and
PDGFR-β [63–65]. Sunitinib is being used in the treatment
of renal cell carcinoma and gastrointestinal stroma tumor.
In a phase II trial of sunitinib, Zhu et al. [48] showed that
that 17 out of 34 patients had SD for at least 12 weeks and
1 had PR. Median progression-free survival (PFS) was 3.9
months and time to progression (TTP) was 4.1 months in
this study, in which sunitinib was administered at a dose of
37.5mg/day.
In a second phase II study of 37 patients with unresec-
table HCC, sunitinib (for four weeks out of every six) at
50mg/day was used. 1 patient achieved PR and 35% had
SD. Median PFS was 3.7 months and median OS, 8 months.
Signiﬁcant toxicities, however, were observed, including four
deaths. This trial was discontinued early due to low response
rate and failure to meet the primary end point [49].
A phase III trial comparing sorafenib with sunitinib
was terminated early as a result of a higher incidence of
serious adverse events in the sunitinib arm compared to
the sorafenib arm and the fact that sunitinib did not meet
the criteria to demonstrate that it was either superior or
noninferior to sorafenib in the survival of patients with
advanced hepatocellular cancer.
7. ABT-869
ABT-869 (Linifanib) is an oral tyrosine kinase inhibitor with
potent activity against both VEGFR and PDGFR [66]. A
phase II open-label, multicenter study of ABT-869 was car-
ried out in 44 patients with unresectable or metastatic HCC
[50].ABT-869atadoseof0.25mg/kgwasadministereddaily
to CP A patients and every other day to CP B patients until
progressive disease or intolerable toxicity. Of the 34 patients
available for analysis, 28 were CP A and 6 CP B. Estimated
response rate was 8.7% for 23 CP A patients. Median TTP
and PFS for all 34 patients were 112 days, and median OS
was 295 days. Most AEs were mild/moderate and reversible
with interruption/dose reductions or the discontinuation of
ABT-869. ABT-869 appears to beneﬁt HCC patients with an
acceptable safety proﬁle. A randomized phase III study in
CP A patients with advanced HCC comparing ABT-869 with
sorafenib is ongoing [67].
8.Brivanib
Brivanib (BMS-582664) is a dual inhibitor of VEGFR and
ﬁbroblast growth factor receptor signaling pathways. It has
shown tumor inhibitory eﬀects in mouse HCC xenograft
models. Raoul et al. [68] conducted a phase II study of
brivanib in pts with advanced or metastatic HCC who had
no prior systemic therapy (Cohort A) or 1 prior regimen
of an angiogenesis inhibitor (Cohort B). 96 patients were
enrolled, 55 in Cohort A and 41 (including 38 who failed
sorafenib) in Cohort B. In Cohort A, median OS was 10
months and median TTP was 2.8 months. Brivanib appears
to have activity as both ﬁrst-line and second-line post-
sorafenib systemic treatment in HCC.
There are ongoing phase III trials assessing brivanib in
both ﬁrst-line setting in comparison with sorafenib as well
as in sorafenib-refractory setting in comparison with best
supportive care in patients with advanced HCC, and results
are awaited [17].
9. EGFRandAnti-EGF/EGFRTherapies
EGFR is overexpressed in 40–70% of HCCs [69], and its acti-
vation is involved in HCC pathogenesis [70, 71]. EGF is
thought to have an important role in tumor angiogenesis,
primarily via the activation of the Raf/MEK/ERK and mTOR
pathways. The receptor may be targeted via antibodies that
block it extracellularly, for example, cetuximab and panitu-
mumab. Intracellular targeting of the EGFR tyrosine kinase
with tyrosine kinase inhibitor such as geﬁtinib and erlotinib
are already in use in the treatment of lung and pancreatic
tumors [72, 73].
Erlotinib and geﬁtinib are among some of the tyrosine
kinase inhibitors that have shown activity in HCC cell lines
and animal models of HCC [74–79].
In a phase II study by Philip et al. [51] of 38 patients with
unresectableHCCusingsingle-agenterlotinib,3(9%)achie-
ved PR, 12 (32%) were progression-free at 6 months, and
the median OS was 13 months. Thomas et al. [52] studied
erlotinib alone in 40 patients with CP class A or B advanced
HCC. Four months-PFS was 43% and 6 months-PFS was
28%.TherewasnoCRorPRandmedianOSwas13.3weeks.
CombiningerlotinibandbevacizumabinaphaseIIstudy
involving 40 HCC patients, Thomas et al. [47]r e p o r t e da
median PFS of 9 months and an impressive median OS of
15.6 months. 12.5% of the patients had CP Class B disease,
and 27.5% had received prior therapy. Side eﬀects included
gastrointestinal bleeding (12.5%), fatigue (20%), hyperten-
sion (15%). After the initiation of screening for and treating
any esophageal varices before being eligible for the study,
there were no further episodes of gastrointestinal bleeding.
An ongoing phase 3 placebo-controlled double-blinded
SEARCH (Sorafenib and Erlotinib, a Randomized Trial
Protocol for the Treatment of Patients with HCC) trial is
being conducted in patients with advanced HCC and CP
Class A liver cirrhosis to determine if the OS seen with
sorafenib in advanced HCC can be improved by the addition
of erlotinib, resulting in combined inhibition of EGF, VEGF,
and the RAS/RAF/MEK signaling pathways [80].
Geﬁtinib (Iressa, Astrazeneca Pharmaceuticals LP, Wilm-
ington DE, USA) has shown activity in preclinical studies in
HCC cell lines and animal models, but these results have not
been matched in clinical studies. In the study by O’Dwyer et
al. [81], single-agent geﬁtinib showed low activity, with 1 out
of31patientsachievingPRand7havingSD.MedianPFSwas
2.8 months, and median OS was 6.5 months.
Cetuximab (IMC-C225 Erbitux; ImClone LLC, New
York, NY and Bristol-Myers Squibb, Princeton, NJ, USA)
is a recombinant chimeric monoclonal immunoglobulin 1International Journal of Hepatology 7
antibody targeting the extracellular domain of the EGFR.
Similar to geﬁtinib, however, it has not shown evidence
of signiﬁcant tumor response in HCC. A small study of
30 patients with unresectable or metastatic HCC showed
no CRs or PRs, with just 5 patients achieving SD and a
median PFS of 1.4 months [82]. Another phase II study by
Gruenwald et al. 2007 [83] of single-agent cetuximab in 32
patients showed only limited activity for the drug with a
median TTP of 2 months.
Because of the multilevel receptor cross-stimulation and
redundant signaling pathways, it is postulated that just
blocking one of these pathways alone may result in others
acting as salvage or escape mechanisms for tumor cells.
There has been evidence that blocking multiple signaling
pathways with a combination of targeted agents may achieve
synergistic antitumor eﬀect [84–88]. Most of the anti-EGFR
studies being carried out now are thus in combination with
cytotoxics or with other targeted agents.
10. mTOR Pathway
Several downstream proteins are activated by the EGF and
insulin growth factor (IGF) signaling pathways, including
phosphoinositide 3-kinase (PI3K), protein kinase B (AKT),
and mTOR (mammalian target of rapamycin). expression
of both IGF and IGF receptor is upregulated in HCC and
human cirrhotic liver [89]. Rapamycin is a natural antibiotic
which is a potent inhibitor of mTOR [90]. Three analogues
of rapamycin have recently been developed and have been
shown to have superior pharmacokinetic and biologic prop-
erties.
Sirolimus (Rapamycin) is an mTOR inhibitor with im-
munosuppressive properties and has been used in the postt-
ransplantation setting. A small pilot study by Rizell and
colleagues showed that 6 out of 21 patients had either SD or
PR [91].
Temsirolimus is a soluble ester analogue, and everolimus
is an orally bioavailable rapamycin derivative. Early clinical
trials have shown these agents to have antineoplastic activity,
and they are currently being tested in various open clinical
trials in the treatment of colorectal, endometrial, and
refractory solid tumors [92–94].
There are currently several ongoing phase I and II trials
studying temsirolimus and everolimus in patients with adva-
nced HCC, either as a single agent or in combination with
another targeted therapy, for example, sorafenib or cytotox-
ics, for example, pegylated doxorubicin.
Both rapamycin and everolimus have been shown in xe-
nografts and mouse models to have activity against HCC,
either singly or in combination for, example, with sorafenib
[95, 96].
Data so far suggests that mTOR inhibitors including the
rapamycinanaloguesarepromisingagents,andseveralongo-
ing trials are exploring this.
11. Conclusion
HCC is a complex disease with multiple signaling pathways
involved in its pathogenesis. It has proven to be a diﬃcult
disease to treat especially in advanced stages. Inhibition of
speciﬁc growth factor receptors and their various signaling
pathways via targeted therapy appears to be a promising
approachforthetreatmentofHCC.Moreworkisrequiredto
fully clarify its molecular pathogenesis and to identify other
key targets for intervention.
The use of combination therapy, either with multiple tar-
geted agents or targeted therapy in combination with conve-
ntional chemotherapy, may be a more eﬀective way of
treating advanced HCC. Combination therapy can target
multiple receptors and signaling pathways. Many of these
combinations have been shown in preclinical studies to
have synergistic eﬀect and may block proposed resistance
pathways [97]. Also, fewer overlapping drug toxicities may
result when blockade at diﬀerent pathways via combination
therapy is used.
Studies are also underway evaluating vertical as well
as horizontal pathway blockade [24]. In vertical blockade,
diﬀerent points along the same pathway are targeted. For
example, the use of bevacizumab (VEGF antibody) together
with sorafenib (multikinase inhibitor with activity against
VEGFR). This may potentially block feedback loops and
lead to more complete blockade. In horizontal blockade,
however, diﬀerent signaling pathways are targeted with
diﬀerent drugs, such as the tandem usage of bevacizumab
with erlotinib (an EGFR tyrosine kinase inhibitor). Trials
combining chemotherapy and other targeted agents with
sorafenib are also underway.
Sorafenib was a major breakthrough as an eﬀective tar-
geted treatment in a selected population of patients with
advanced HCC. There is an interest in its being used in
an adjuvant or neoadjuvant setting in patients undergoing
locoregional therapies and even as a chemopreventive in
cirrhotic patients.
Other new pathways and molecular targets being inves-
tigated include resistance and apoptosis pathways. Also,
identifying both predictive and prognostic biomarkers in
patients with HCC will be the next step in helping to better
tailor HCC treatment.
Muchworkremainstobedonetoidentifynewmolecular
targets, assess the role of targeted therapy in the adjuvant,
neoadjuvant, and metastatic setting, determine the various
combinations of treatment, either tandem targeted agents
or with conventional cytotoxics, and evaluate the role of
sequential versus concurrent therapy.
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